Kanvas Biosciences develops a spatial biology platform for microbiome drug screening, discovery and manufacturing aimed at accelerating live biotherapeutics development. The company’s lead program is KAN-001, an immuno-oncology candidate for which the recent Series A will fund clinical trials. Kanvas intends to use proceeds to advance commercial partnerships alongside clinical development. Its core technology was initially developed at Cornell University and is exclusively licensed. The company is led by CEO Matthew Cheng. The articles do not report revenue, user metrics, founding year, or prior financing details.

Total raised

$73M

Funding rounds

3

Latest round

Series A

Latest activity

May 2026